Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Todd Neale

November 21, 2022

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

Shelley Wood

February 28, 2020

News Daily News

Women Bleed More Than Men After PCI, GLOBAL LEADERS Affirms

Todd Neale

November 07, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Daily News

Surgery Common in Stented Patients But Newer Stents Appear to Reduce Potential Risks

Michael O'Riordan

December 07, 2015

News Features

Despite New Findings, Optimal DAPT Duration Still Up in the Air

Todd Neale

December 10, 2014

News Conference News EuroPCR 2014

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

Yael L. Maxwell

May 21, 2014

News Daily News

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

May 20, 2014

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

News Daily News

PRODIGY Published: No Advantage to Long-term Clopidogrel

April 03, 2012

Advertisement

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

Women Bleed More Than Men After PCI, GLOBAL LEADERS Affirms

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Surgery Common in Stented Patients But Newer Stents Appear to Reduce Potential Risks

Despite New Findings, Optimal DAPT Duration Still Up in the Air

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

PRODIGY Published: No Advantage to Long-term Clopidogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content